BioCentury
ARTICLE | Clinical News

Azimilide: Phase III

November 19, 2001 8:00 AM UTC

In a placebo-controlled international Phase III study in 3,717 post-MI patients with a low left ventricular ejection fraction, azimilide had no adverse effect on all-cause mortality or survival. Patie...